In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently diagnosed in patients with cardio-pulmonary comorbidities, which poses ...

New data from the single-center, open-label extension EDITA-ON study suggest that early treatment for pulmonary arterial hypertension (PAH) could benefit patients with systemic sclerosis and early ...

Future Cardiol. 2013;9(3):335-349. The pivotal trial that established sildenafil as a treatment for WHO Group 1 PH was the SUPER trial. [102] SUPER enrolled WHO functional class II and III PAH ...

Please provide your email address to receive an email when new articles are posted on . Comparable proportions of patients with vs. without a mental health comorbidity took PAH monotherapy, dual ...

The company received FDA approval to initiate a late-stage study of IKT-001Pro for pulmonary arterial hypertension, backed by $275 million in funding. IKT-001Pro, a modified version of imatinib, aims ...

New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...

Please provide your email address to receive an email when new articles are posted on . Sotatercept plus background therapy yielded several benefits in adults with pulmonary arterial hypertension over ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries in your lungs. It happens when these arteries become narrow or blocked, making it harder for blood to flow ...

WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone “Pulmonary arterial hypertension ...

The US Food and Drug Administration has approved the injectable biologic sotatercept-csrk (Winrevair) for the management of adults with pulmonary arterial hypertension (PAH), drugmaker Merck announced ...

On March 26th, the US FDA granted approval for Merck’s WINREVAIR™ (sotatercept-csrk), marking a significant milestone in pulmonary arterial hypertension (PAH) treatment. PAH, characterized by elevated ...